CV Sciences, Inc. Reports Third Quarter-End 2026 Financial Results
Key Highlights
- ➤Revenue $3.0 million, down 7.0% year over year
- ➤Gross margin reached 50.0%, up from 48.5% year over year
- ➤Adjusted EBITDA turned positive at $32,000 versus prior-period losses
- ➤Operating expenses fell 11.6% year over year to $1.6 million
- ➤Federal hemp-product provisions are scheduled to take effect December 11, 2026
Expert Statements
Joseph Dowling, Chief Executive Officer of CV Sciences
“Our third quarter results demonstrate continued progress in strengthening the operating performance of our business despite ongoing regulatory challenges and pressure on revenue. We expanded gross margins to 50.0%, reduced operating expenses by 11.6% year over year, and achieved positive adjusted EBITDA of $32,000, compared to adjusted EBITDA losses in both the prior-year quarter and the second quarter of 2026. These results reflect our continued focus on cost discipline, operational efficiency, and improving the underlying profitability of our business. At the same time, we continue to advance our product innovation and diversification strategy. Products launched since January 2023 accounted for 48% of our third quarter net revenue, demonstrating the growing contribution of our newer product offerings. During the quarter, we further expanded our +PlusHLTH™ portfolio with personalized wellness solutions designed to support healthy aging. Looking ahead, we remain focused on strengthening our established brands, expanding our presence in broader science-based wellness categories, maintaining disciplined capital allocation, and pursuing strategic opportunities that support sustainable growth and long-term shareholder value”
SAN DIEGO, CA / ACCESS Newswire / November 12, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, today announced its financial results for the quarter ended September 30, 2026.
Third Quarter 2026 and Recent Financial and Operating Highlights, and Regulatory Update * Generated revenue of $3.0 million for the third quarter 2026 compared to $3.3 million for the third quarter 2025 and compared to $3.0 million for the second quarter 2026; * Recognized gross margin of 50.0% for the third quarter 2026 compared to 48.5% for the third quarter 2025 and compared to 48.6% for the second quarter 2026; * Reduced operating expenses by 11.6% to $1.6 million for the third quarter 2026 compared to $1.8 million for the third quarter 2025, and by 6.6% from $1.7 million in the second quarter 2026, excluding the benefit from the gain on legal settlement; * Recognized positive adjusted EBITDA of $32,000 for the third quarter 2026 compared to adjusted EBITDA losses of $118,000 for third quarter 2025 and $132,000 for the second quarter 2026; * Cash balance of $0.3 million at quarter and year end; * Strengthened our financial position by increased working capital of $0.7 million at quarter end, significantly improved from $0.1 million at year end; * Expanded the +PlusHLTH™ portfolio with personalized wellness solutions for healthy aging; and * Continued monitoring of potential updates to the implementation of restrictive federal provisions for hemp-derived cannabinoid products which are currently scheduled to be in effect on December 11, 2026. "Our third quarter results demonstrate continued progress in strengthening the operating performance of our business despite ongoing regulatory challenges and pressure on revenue. We expanded gross margins to 50.0%, reduced operating expenses by 11.6% year over year, and achieved positive adjusted EBITDA of $32,000, compared to adjusted EBITDA losses in both the prior-year quarter and the second quarter of 2026. These results reflect our continued focus on cost discipline, operational efficiency, and improving the underlying profitability of our business.
Get started
Create a free account to read the full story.